A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

NCT02920385 · Completed

Last updated 2026-05-28

This clinical trial is testing how a diabetes medication called oral semaglutide affects the levels of thyroid medication (levothyroxine) in healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 45 people

Who can join Ages 18–50 · all sexes Healthy volunteers accepted.

Timeline Started 2016-10 · est. completion 2017-06

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02920385 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate the influence of oral semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of semaglutide administered orally in healthy subjects.

Treatments tested

Semaglutide Drug

Oral administration once daily alone or together with levothyroxine or Placebo
SNAC Drug

Oral administration once daily alone or together with levothyroxine or semaglutide
Levothyroxine Drug

Oral administration alone or together with SNAC or oral semaglutide
Placebo Drug

Oral administration once daily together with semaglutide

Main thing measured	Baseline-corrected area under the total T4 serum concentration-time curve from 0 to 48 hours after a single dose of levothyroxine
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02920385 ↗